The EMEA's CHMP has recommended the contraindication of certain erectile dysfunction therapies in patients with single-eye vision loss

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1102, 2006-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

EMEA's CHMP has recommended updating the product information for natalizumab [Tysabri] to further increase the awareness about risk of progressive multifocal leukoencephalopathy (PML)

By  

Reactions Weekly, Vol. 1, Iss. 1222, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Looking to the Future for Erectile Dysfunction Therapies

By Hatzimouratidis Konstantinos   Hatzichristou Dimitrios G.  

Drugs, Vol. 68, Iss. 2, 2008-01 ,pp. : 231-250

Adis International

Access to resources Recommend Favorite

Emerging pharmacological therapies for erectile dysfunction

By Gingell J.   Lockyer R.  

Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 12, 1999-12 ,pp. : 1689-1696

Informa Healthcare

Access to resources Recommend Favorite

Economic aspects of medical erectile dysfunction therapies

By Anastasiadis Aristotelis G   Ghafar Mohamed A   Shabsigh Ridwan   Burchardt Martin  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 3, 2002-03 ,pp. : 257-263

Informa Healthcare

Access to resources Recommend Favorite

The Triumvirate of Erectile Dysfunction Therapies: Is There Room for Three?

By  

Pharmaceutical & Diagnostic Innovation, Vol. 1, Iss. 3, 2004-01 ,pp. : 21-23

Adis International

Access to resources Recommend Favorite